Perspectives of Japanese patients on psoriatic disease burden: Results from “Psoriasis and Beyond,” the Global Psoriatic Disease Survey
The Journal of Dermatology · 2024
DOI: 10.1111/1346-8138.17424 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Masanori Okuse und 6 weiteren Autor:innen. Beteiligte Einrichtung: Japan Psoriasis Association, Tokyo, Japan. Hauptthemen laut MEDLINE: Quality of Life, Psoriasis, Cost of Illness, Arthritis, Psoriatic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Maruho Co., Ltd, Novartis Pharma K.K.
Abstract (Originalsprache)
Psoriatic disease (PsD) is a chronic disease affecting skin (psoriasis) and joints (psoriatic arthritis, PsA) that has a significant impact on patients' quality of life (QOL). We report findings from the Japanese subgroup of patients included in Psoriasis and Beyond: The Global Psoriatic Disease Survey, a cross‐sectional, quantitative online survey of patients with self‐reported, healthcare professional (HCP)‐diagnosed, moderate‐to‐severe plaque psoriasis, with or without PsA. Eligible patients who were recruited online completed a 25‐min internet‐based survey in Japanese. We assessed patients' understanding of the systemic nature of PsD, disease burden, perception towards their HCPs, treatment expectations, and satisfaction with care. Of the 148 patients, 74% were females. In total, 65% of patients were aware of the systemic nature of their disease. A minority of patients (27%) were aware that PsA was related to their psoriasis, and 30% and 42% of patients were unaware of any manifestations and comorbidities, respectively, related to PsD. Overall, 21% of patients reported that their disease has a “very large” to “extremely large” impact on their QOL (assessed by Dermatology Life Quality Index score), while the majority (61%) reported a “small” effect or “no effect” at all on QOL. Patients experienced stigma and discrimination and had a negative impact on relationships due to PsD. More patients with psoriasis and concomitant PsA (66%) were satisfied with their current treatment than those with psoriasis alone (46%). Overall, 41% of patients were not involved in deciding their treatment goals. These results suggest that Japanese patients may not be fully aware of the systemic nature of PsD, its manifestations and comorbidities. While these patients were somewhat satisfied with their current treatment, they were only occasionally consulted in deciding treatment goals. Policy measures are required to address the stigma and discrimination experienced by patients. Increased patient participation in their care supports shared decision‐making and enhanced treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Japan Psoriasis Association, Tokyo, Japan.
- Novartis Pharma K.K, Tokyo, Japan.
- IFPA, Stockholm, Sweden.
- Novartis Pharma AG, Basel, Switzerland.
- Department of Dermatology, Tokyo Medical University, Tokyo, Japan.
ORCID-Profile: Yukari Okubo
Förderung
- Maruho Co., Ltd
- Novartis Pharma K.K
Zitieren
APA
Okuse, M., Soekawa, M., Itakura, A., Kawamura, T., Mburu, S., Frade, S., & Okubo, Y. (2024). Perspectives of Japanese patients on psoriatic disease burden: Results from “Psoriasis and Beyond,” the Global Psoriatic Disease Survey. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17424
Vancouver
Okuse M, Soekawa M, Itakura A, Kawamura T, Mburu S, Frade S, et al. Perspectives of Japanese patients on psoriatic disease burden: Results from “Psoriasis and Beyond,” the Global Psoriatic Disease Survey. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17424
BibTeX
@article{Okuse2024,
author = {Okuse, Masanori and Soekawa, Masayuki and Itakura, Asako and Kawamura, Taisuke and Mburu, Sicily and Frade, Susan and Okubo, Yukari},
title = {Perspectives of Japanese patients on psoriatic disease burden: Results from “Psoriasis and Beyond,” the Global Psoriatic Disease Survey},
journal = {The Journal of Dermatology},
year = {2024},
doi = {10.1111/1346-8138.17424}
}
EUVIMED